Abstract:The presence of EGFR activating mutations and ALK chromosomic rearrangements with corresponding tyrosine kinase inhibitors (TKIs) has revolutionized the treatment strategies of patients with non-small cell lung cancer (NSCLC). Although tremendously initial response and manageable toxicity profiles, acquired resistance inevitably develops after approximately 1 year treatment with EGFR-TKIs (erlotinib and gefitinib) and ALK inhibitor (crizotinib). Encouragingly, third-generation EGFR-TKIs including AZD9291, CO1686 and brigatinib have showed striking efficacy overcoming acquired resistance driven by T790M secondary mutations. Other novel third-generation EGFR-TKIs such as ASP8274, EGF816, PF-06747775 and avitinib are also being investigated in early-stage clinical trials and the survival and safety data will be released in the near future. Another promising novel EGFR-TKI, namely AZD3759 has showed promising response in patients with brain metastases and leptomeningeal disease. Recently, EAI045, an EGFR allosteric inhibitor, in combination with cetuxmab exhibit antitumor activity in mouse models of lung cancer driven by L858R/T790M/C797S, a resistant mutation of AZD9291. Meanwhile, second-generation ALK inhibitors (ceritinib and alectinib) have entered clinical applications for NSCLC patients with ALK rearrangements after failure of crizotinib and third-generation ALK inhibitors (lorlatinib and ASP3026) are also being evaluated in clinical trials overcoming known ALK resistant mutations. On the other hand, with the development of high-throughput sequencing, called next-generation sequencing (NGS) and genomic technologies, more novel molecular targets such as MET 14 exon skipping splicing mutations have been identified as potential therapeutic targets and simultaneously analyzing hundreds of molecular alterations have turned out reality with limited tumor tissues. In the recent years, the emergence of numbers of oncogenic drivers other than EGFR mutations and ALK rearrangements has divided NSCLC into multiple distinct subtypes amenable to corresponding targeted therapy. For instance, dabrafenib either as monotherapy or in combination with MEK inhibitor (trametinib) has displayed promising antitumor activity and manageable safety profile in patients with BRAF V600E mutations, accounting for around 1.4% of patients with NSCLC. Other novel molecular targets maybe serving as oncogenic drivers including mutations in HER2 (neratinib and pyrotinib) and PI3KCA (BKM120 and GDC0941), ROS1 (entrectinib, foretinib and lorlatinib), RET (XL184) and NTRK (entrectinib) rearrangements and FGFR1 gene amplification (AZD4547, Lenvatinib and FP-1039) are being evaluated either in preclinical settings or early-stage clinical trials. Section not applicable Section not applicable Section not applicable

New Approaches for Individual Treatment of Advanced Non-Small Cell Lung Cancer

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives

Erlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer: an Update for Clinicians

PUB007 Novel TKIs in Non-Small Cell Lung Cancer

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

The Emerging Treatment Landscape Of Advanced Non-Small Cell Lung Cancer

Targeted Therapies for Patients with Advanced NSCLC Harboring Wild-Type EGFR: What’s New and What’s Enough

New Trends of Advanced Non-Small Cell Lung Cancer Therapy

Medical Treatment of Advanced Non-Small Cell Lung Cancer: Progress in 2014

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Recent progress in targeted therapy for non-small cell lung cancer

New promises and challenges in the treatment of advanced non-small-cell lung cancer

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer

Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer

Update on Targeting EGFR in Advanced Non-Small-cell Lung Cancer

Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Research progress on drug resistance mechanism and management of targeted therapy for ALK-positive non-small cell lung cancer

Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.